Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

  • There is currently no data for POLX

Director Dealing

22 Jan 2020 16:03

RNS Number : 6364A
Polarean Imaging PLC
22 January 2020
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Director Dealing

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that yesterday it was notified that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 337,574 Ordinary Shares of £0.00037 ("Ordinary Shares") at an average price of 29.6 pence per share on 20 January 2020.

Following this transaction, Dr Allis now holds a beneficial interest in 1,877,574 Ordinary Shares, representing approximately 1.64 per cent. of the Company's issued share capital.

 

Enquiries: 

 

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com 

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

Richard Morgan, Chairman 

 

 

 

SP Angel Corporate Finance LLP 

Tel: +44 (0)20 3470 0470  

David Hignell / Soltan Tagiev (Corporate Finance) 

 

Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Dr Jonathan Allis

2.

Reason for the notification

a)

Position/status:

Non-Executive Director

b)

Initial notification/Amendment:

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Polarean Imaging Plc

b)

LEI:

213800DGR2BHXJ36OL37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

 

Ordinary shares of £0.00037

GB00BF3DT583

b)

Nature of the transaction:

Purchase of shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

29.9 pence

33,444

29.9 pence

33,444

29.9 pence

33,444

29.5 pence

33,898

29.5 pence

67,796

29.5 pence

50,847

29.5 pence

50,803

29.5 pence

33,898

 

d)

Aggregated information:

Aggregated volume:

Price:

 

Price(s)

Volume(s)

29.6 pence

337,574

 

 

 

e)

Date of the transaction:

20 January 2020

f)

Place of the transaction:

AIM, London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGZGZMVZGGGZM
Date   Source Headline
23rd Dec 20257:00 amRNSCancellation - Polarean Imaging Plc
15th Dec 20254:03 pmRNSResult of General Meeting
1st Dec 20257:00 amRNSChest coil passes Philips compatibility testing
25th Nov 20257:00 amRNSFirst Xenon Hyperpolariser in Asia
24th Nov 20257:00 amRNSKorean distributor agreement with DK Healthcare
14th Nov 20257:00 amRNSProposed Cancellation of Admission & Notice of GM
27th Oct 20253:37 pmRNSHolding(s) in Company
22nd Oct 20257:00 amRNSStrategic review and consideration of AIM listing
6th Oct 20257:00 amRNSAscend Imaging agreement expansion
29th Sep 20257:00 amRNSUniversity of Virginia Health Hospital agreement
25th Sep 202512:14 pmRNSNational Institutes of Health system order
25th Sep 20257:00 amRNSHalf-year Report
16th Sep 20257:00 amRNSNotice of Results
11th Sep 20254:36 pmRNSHolding(s) in Company
12th Aug 20257:00 amRNSSubmission of new Phase III study protocol to FDA
24th Jul 20257:00 amRNSBlock Listing Six Monthly Return
24th Jun 20257:00 amRNSPromotion & sales representative agreement
9th Jun 20254:16 pmRNSResult of AGM
2nd Jun 20257:00 amRNSFDA expands XENOVIEW indication
21st May 20257:00 amRNSDr. Bastiaan Driehuys awarded by ATS
15th May 202512:48 pmRNSXenon MRI featured prominently at ATS 2025
14th May 20252:25 pmRNSOngoing collaboration with Philips
8th May 20257:00 amRNSFinal Results
6th May 20252:59 pmRNSHolding(s) in Company
25th Apr 20257:00 amRNSNotice of Results
10th Mar 20257:00 amRNSExpansion of Xenon MRI imaging platform
27th Feb 20257:00 amRNSFY24 trading update
19th Feb 20257:00 amRNSVirtual Investor Day
3rd Feb 20257:00 amRNSTaiwanese distributor agreement with Sumtage
30th Jan 20257:00 amRNSKey patent in China secured
28th Jan 20257:00 amRNSCollaboration to Advance Lung Imaging Innovation
24th Jan 20257:00 amRNSBlock Listing Six Monthly Return
11th Dec 20242:52 pmRNSHolding(s) in Company
21st Nov 20247:00 amRNSFDA clears Chest Coil in GE HealthCare MRI Systems
25th Sep 20247:00 amRNSVirtual investor day
4th Sep 20247:00 amRNSHalf-year Report
3rd Sep 20247:00 amRNSAppointment of Vice President of Sales
28th Aug 20247:00 amRNSAppointment of Chief Medical Advisor
21st Aug 20247:00 amRNSNotice of Results
15th Aug 20247:00 amRNSAppointment of Bastiaan Driehuys as consultant
1st Aug 20247:00 amRNSFDA submission to expand minimum age for XENOVIEW™
31st Jul 20247:00 amRNSNew Xenon MRI System trade-in agreement
29th Jul 20247:00 amRNSRepricing of Options and Grant of Options
26th Jul 20247:00 amRNSBlock Listing Six Monthly Return
24th Jul 20242:36 pmRNSResult of AGM
19th Jul 202410:36 amRNSXenon MRI System trade-in agreement
18th Jul 20245:33 pmRNSPDMR Dealing
28th Jun 20247:00 amRNSFinal Results
19th Jun 20245:23 pmRNSHolding(s) in Company
19th Jun 20245:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.